The Effect of Age on Immunologic Response to Recombinant Hepatitis B Vaccine: A Meta‐analysis
Citations Over TimeTop 10% of 2002 papers
Abstract
Hepatitis B vaccine is a key tool for the prevention of hepatitis B infection. Age-associated changes in immune function may contribute to decreased vaccine efficacy in older individuals, although research related to this topic has yielded contradictory findings. We performed a meta-analysis of 24 published trials and studies that evaluated the association of age with response to hepatitis B vaccine, using a random-effects model. Pooling of study results suggested a significantly increased risk of nonresponse to hepatitis B vaccine among older individuals (relative risk [RR], 1.76; 95% confidence interval [CI], 1.48-2.10). An elevated risk of nonresponse persisted even after exclusion of poor-quality studies (RR, 1.63; 95% CI, 1.23-2.15) and adjustment for publication bias (RR, 1.52; 95% CI, 1.26-1.83), and it was present even when "older" individuals were defined as being as young as 30 years. These findings have important implications for individuals at risk for hepatitis B infection, including health care workers and travelers.
Related Papers
- → Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial(1999)174 cited
- Research on Control of the Outbreak of Hepatitis A Using Inactivated Hepatitis A Vaccine(2007)
- Result of Boosting of Inactivated Hepatitis A Vaccine Healive(2003)
- Assessment on Booster Immunization in Healthy Children with Inactivated Hepatitis A Vaccine and Hepatitis A and Hepatitis B Combined Vaccine(2013)
- The immunogenicity and safety study of concurrent hepatitis A and hepatitis B vaccination in recruits(2004)